Hepion in-licenses diagnostic tests from New Day Diagnostics for $0.725M upfront

Hepion Pharmaceuticals, Inc.

In-licensed celiac, respiratory multiplex (COVID/flu A/B/RSV), H. pylori, and HCC tests; three have CE marks for EU sale.
Upfront consideration: $525k cash + $200k in unregistered common stock to New Day Diagnostics.
Milestone payments up to $17.15M on regulatory, sales, and reimbursement milestones; royalties in upper single to low double digits.
Binding LOI is effective immediately; termination requires mutual consent. Parties to execute definitive license agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.